Work

Anaphylaxis and Anesthesia: Controversies and New Insights

Year: 2009
Type: review
Abstract: PERIOPERATIVE anaphylaxis may be a life-threatening clinical condition and is typically a result of drugs or substances used for anesthesia or surgery. After anaphylaxis, allergologic assessment is essential to identify the offending agent and prevent recurrences, because no preemptive therapeutic strategies exist. This review seeks to (1) identify the clinical diagnostic pathway necessary to distinguish anaphylaxis from confounding clinical diagnoses, (2) discuss the more common allergens that cause anaphylaxis during anesthesia, (3) discuss a rational approach to the identification of the offending allergen through blood and skin testing that allows for the safe future clinical management of patients experiencing perioperative anaphylaxis, and (4) discuss new therapeutic perspectives for the management of patients whose hemodynamic collapse is unresponsive to catecholamines, the initial recommended pharmacologic intervention.Anaphylaxis occurring during the perioperative period is a clinical syndrome involving multiple organ systems. The clinical manifestations are the consequences of the immediate as well as ongoing release of preformed mediators from mast cells and basophils. Careful consideration must therefore also be given to the monitoring of the patient after the management of anaphylaxis.1,2In the early 2000s, the European Academy of Allergology and Clinical Immunology proposed to define this acute nosologic entity as "a severe, life-threatening, generalized or systemic hypersensitivity reaction,"3primarily mediated by type E immunoglobulins (IgEs). More recently, this clinical entity was defined by the second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium as follows: "Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death."4The European Academy of Allergology and Clinical Immunology committee recommended that the term anaphylactoid , introduced for non–IgE-mediated anaphylactic reactions, should no longer be used,3but this proposal has not been universally accepted.4Classically, IgE isotype antibodies are produced on an initial exposure to an allergen in susceptible individuals and bind to high-affinity FCϵRI receptors located in the plasma membrane of tissue mast cells and blood basophils, whereas lymphocytes, eosinophils, and platelets bind IgE antibodies via low-affinity FCϵRII receptors. This initial phase of sensitization is clinically silent. On reexposure, the multimeric allergen cross-links two specific IgE receptors, creating a bridge between two IgEs. The two IgE receptors aggregate and induce a signal transduction cascade releasing systemically preformed biochemical mediators, including histamine, neutral proteases (tryptase, chymase), and proteoglycans (heparin) from intracellular granules in cells within tissues and blood. Some of these mediators, such as histamine, lead to increased nitric oxide production.5Newly formed proinflammatory phospholipid-derived mediators, including prostaglandin D2, leukotrienes, thromboxane A2, and platelet-activating factor, are released soon after. Thereafter, mast cells release numerous chemokines and cytokines that initiate recruitment and activation of additional inflammatory cells.One key issue of anaphylaxis is that a very small amount of allergen is sufficient for the cells to react. The involved target organs commonly include the skin, mucous membranes, cardiovascular and respiratory systems, and the gastrointestinal tract. The corresponding clinical signs are erythema, edema, pruritus, arterial hypotension, tachycardia, and bronchial and gastrointestinal smooth muscle constriction, described by the Ring and Messmer clinical severity scale, which was adapted to describe perioperative immediate reactions (table 1).6Although this scale does not take into account the pathophysiologic mechanisms, it is appropriate for grading the clinical severity and guiding the clinical care of immediate reactions.1,7In vivo and in vitro procedures can be used to differentiate between allergic (where an immune mechanism can be demonstrated, i.e. , an anaphylactic mechanism) and nonallergic (also previously called anaphylactoid , where an immune mechanism is ruled out) hypersensitivity reactions.The overall incidence of perioperative anaphylaxis is estimated at 1 in 10,000–20,000 anesthetic procedures, whereas it is estimated at 1 in 6,500 administrations of neuromuscular blocking agents (NMBAs).8Its exact incidence remains underestimated as reactions are underreported.Anaphylaxis is one of the rare clinical events specifically related to anesthesia leading to perioperative morbidity and mortality. Morbidity remains unknown. In France, 3% of the deaths that are partially or totally anesthesia related involve anaphylaxis,9whereas 10% of perioperative immediate hypersensitivity reactions reported to the United Kingdom Medicines Control Agency are fatal.2Nevertheless, this latter datum should be interpreted cautiously because many less severe reactions are probably not reported.2In France, NMBAs were shown to be the most common agents involved, followed by latex and antibiotics. In a Norwegian single-center study, NMBAs were most commonly involved, with latex implicated in very few cases and with no causal agent identified in one third of the cases.10Conversely, in two Spanish centers, antibiotics followed by NMBAs were the main agents involved.11Anaphylaxis to NMBAs is not uncommon in patients without any known previous exposure to any NMBA.2,11In this particular clinical setting of anaphylaxis after a first-time NMBA administration, the source and the nature of the sensitizing agent remain unknown.12However, quaternary ammonium ions are suggested to be the allergenic determinants in NMBAs.12Commonly used chemicals, such as toothpastes, detergents, shampoos, and cough medicines, share these determinants with NMBAs. In a predisposed individual, these common chemicals might be one of the contributing factors promoting sensitization to quaternary ammonium ions and creating the risk for developing anaphylaxis to NMBAs.2Recently, it has been suggested that the sensitization to quaternary ammonium ions seems to be related to exposure to pholcodine, a cough-relieving medicine.12Moreover, an individual can have uneventful previous exposures to a specific drug (e.g. , NMBAs, antibiotics), which does not preclude the risk of anaphylaxis after a subsequent administration of this drug.2The etiologic diagnosis of an immediate reaction occurring during anesthesia relies on a triad including clinical, biologic, and allergologic evidence (fig. 1).The initial diagnosis of anaphylaxis is presumptive, although essential, because anaphylaxis may progress within minutes to become life-threatening. The first line of evidence for the diagnosis of anaphylaxis includes the features and severity of clinical signs and the timing between the introduction of a suspected allergen and the onset of symptoms, whereas the required dosage for resuscitative medications gives insight as to the severity of the reaction.1The clinical features occurring during anesthesia may involve cardiovascular symptoms (tachycardia, bradycardia, cardiac arrhythmias, hypotension, cardiovascular collapse, cardiac arrest), bronchospasm, and cutaneous–mucous signs (erythema, urticaria, angioedema).1,2,7,8They are described according to the Ring and Messmer four-step grading scale adapted as follows (table 1).1,6,7Grade I involves cutaneous–mucous signs, whereas grade II corresponds to mild cutaneous–mucous features that may be associated with cardiovascular and/or respiratory signs. The cardinal sign of grade III is cardiovascular collapse that may be associated with cutaneous–mucous signs and/or bronchospasm, and grade IV is cardiac arrest. Grades I and II are usually not life-threatening conditions, whereas grades III and IV correspond to emergency situations necessitating prompt resuscitation.Perioperative anaphylaxis usually occurs within minutes, even 1 min, after anesthetic induction and is primarily linked to agents administered intravenously.1The most commonly reported initial clinical features during severe reactions (grade III or IV) are pulselessness, desaturation, and difficult lung inflation due to severe bronchospasm. Respiratory signs are enhanced in patients with underlying asthma and/or chronic obstructive pulmonary disease. Asthmatic patients experiencing perioperative anaphylaxis are therefore more likely to exhibit bronchospasm.1,2Cardiovascular symptoms often include hypotension and tachycardia but may rapidly progress into severe arrhythmias and cardiovascular collapse if not recognized and treated in a timely fashion.1Because cardiovascular disturbances are the hallmark of severe anaphylaxis, cardiovascular collapse as the sole feature or cardiac arrest may be the inaugural event.1,2,7,8Acute coronary events associated with hypersensitivity reactions were recently referred to as Kounis syndrome , which is also called allergic angina or allergic myocardial infarction .13Two variants were described as the consequences of mast cell mediator release: type I includes patients without predisposing factors for coronary artery disease, whereas type II includes patients with predisposing factors. The allergic reaction may induce coronary artery spasm with normal cardiac-specific enzymes in variant I, whereas acute infarction may be seen in both groups (types I and II). A threshold level of mast cell content has been suggested to be involved in the occurrence of such events.13Three predictive criteria of the severity of an ongoing anaphylactic reaction, which may or may not be associated, include the following: (1) The more rapidly anaphylaxis occurs after allergen exposure, the more likely the reaction is to be severe and potentially life-threatening.14(2) Cutaneous signs may be absent in rapidly progressive anaphylaxis.14Accordingly, the subcutaneous vascular bed is susceptible to vasoconstrictive influences during anaphylaxis (being the first vascular bed compromised when circulatory homeostasis is threatened). Cutaneous signs may therefore only appear after the normalization of blood pressure. Consequently, the absence of initial cutaneous vasodilatation should not preclude the diagnosis of anaphylaxis. (3) Another potentially confounding sign might be bradycardia, which can be seen in massive hypovolemia, probably as a result of the Bezold–Jarisch reflex, a cardioinhibitory reflex that has its origin in sensory receptors of the left ventricle transmitted by unmyelinated vagal C fibers.14This paradoxical bradycardia occurring during extreme hypovolemia has been reported to occur in as many as approximately 10% of patients with anaphylaxis during anesthesia.2In this case, bradycardia may be considered as a life-protecting adaptive mechanism that allows the ventricles to fill before they start contracting again despite a massive hypovolemia. Therefore, this specific event during anaphylaxis must be recognized by the anesthesiologist caring for the patient because the administration of atropine in direct response to the symptom of bradycardia might directly induce a circulatory arrest, the adequate treatment in this setting being a large volume expansion followed by epinephrine.The most commonly involved agents in perioperative anaphylaxis are NMBAs, latex, and antibiotics. Anaphylaxis usually occurs shortly after induction,1,7with NMBAs or antibiotics being primarily involved,7but anaphylaxis may occur any time with all potentially allergenic agents.1Dyes, hypnotic agents, local anesthetics, opioids, colloids, aprotinin, protamine, chlorhexidine, and contrast agents are less frequently involved.1,2,7Latex-induced anaphylaxis usually occurs up to 30–60 min after the beginning of the surgery but may occur immediately.2,15Severe and even fatal reactions to latex are now reported.16Attempts to ban latex from use in clinical products is therefore encouraged because the incidence of latex-induced anaphylaxis has increased dramatically during the past two decades, especially in high-risk groups of patients such as children or adults requiring multiple surgical procedures or healthcare workers.17Anesthesiologists themselves have a high prevalence of latex sensitization, which may have a genetic basis.18Accordingly, in a pediatric hospital including operating rooms and perioperative care areas, no allergic reaction to latex has been reported in 25,000 anesthetized children or in healthcare workers when a latex-free environment policy has been adopted.17Finally, the onset and type of symptoms depend on the allergen concentration,19whereas the length of symptoms (up to 36 h) may vary according to the mode of injection (e.g. , when using dyes such as isosulfan blue or patent blue for lymphatic mapping and sentinel lymph node biopsy). Moreover, the patient's sensitivity level and route of administration are important in determining the onset and severity of symptoms. For example, intravenous and mucous membrane exposure are likely to be associated with a faster onset of more severe symptoms.19Biochemical tests are available, either in vivo or in vitro .Histamine is a preformed inflammatory mediator contained in granules of mast cells and basophils. An early increase in plasma histamine concentration indicates activation of mast cells and/or basophils and is observed during allergic or nonallergic mechanisms. Conversely, the absence of histamine increase does not preclude an immunologic or nonimmunologic mechanism. The plasma half-life of histamine is assumed to be very short (15–20 min).7Blood samples for histamine measurement should therefore be drawn within 30 min after a grade I or II reaction. After severe reactions (grades III and IV), histamine may still be increased 2 h after the reaction, probably because of the saturation of the enzymatic metabolism of histamine allowing for the detection of increased histamine levels for this prolonged period after the reaction.7Tryptase is a mast cell neutral serine protease and a preformed enzyme. Two major forms have been identified2,20: α-Tryptase is secreted constitutively and is increased in mastocytosis, whereas pro–β-tryptase also secreted constitutively serves as a measure of mast cells mass. Mature β-tryptase is preferentially stored in mast cells granules and, when systemically released, reflects mast cell activation with mediator release.Serum tryptase concentrations reach a peak between 15 min and 1 h and decline under apparent first-order kinetics with a half-life of approximately 2 h.1,2,7Therefore, blood samples may be drawn within 15 and 60 min in grade I or II reactions and within 30 min and 2 h in grade III or IV reactions.1,7An increase of total tryptase concentrations (i.e. , the sum of α- and β-tryptase) is highly suggestive of mast cell activation as seen in anaphylaxis, but its absence does not preclude the diagnosis (grades I and II). Conversely, an increase of tryptase may be seen during nonallergic mechanisms, although less pronounced when compared with immunologic mechanisms.2,20To compare the concentrations with baseline levels, a new sample of tryptase can be taken either at least more than 24 h after the reaction or when the patient is referred for investigation.1,7,20Finally, tryptase concentrations may remain increased in cases of late-onset, biphasic anaphylaxis or when associated with an underlying mastocytosis2,19,20(fig. 2).In clinical situations of an immediate nonallergic reaction (e.g. , histamine release), histamine may be increased, whereas tryptase usually remains normal. In contrast, because histamine and tryptase concentrations correlate with the severity of the allergic reaction,7combined histamine and tryptase measurements have been recommended for the diagnosis of immediate reactions,7whereas others recommend only tryptase.1,2,20This constitutes the second component of the triad.Other in vitro tools have been proposed in clinical practice but are not available everywhere. No NMBA-specific IgE assay is currently available, except for suxamethonium, and its sensitivity remains low (30–60%).20Some authors suggested the use of a quaternary ammonium (choline analog) or morphine-based solid-phase IgEs to evaluate sensitization to the quaternary ammonium of NMBAs.12,20In vitro specific IgE assays are also available for a few other anesthetics (thiopental, propofol), antibiotics (amoxicillin, cefaclor, penicillin G and V), or latex.2,7,20Nevertheless, specific IgE assays seem to be less sensitive than skin tests.12Finally, serum IgEs provide a possible explanation of the mechanism but do not prove that the drug or agent is responsible for the reaction.2Several other tests are proposed for the indirect detection of specific IgEs to anesthetic drugs. The leukocyte histamine release test is reliable when cross-reactivity among NMBAs is investigated for NMBA reintroduction.1,7The quantification of in vitro –activated basophils (CD63 and CD203c) after challenge with the culprit agent using flow cytometric analysis might be a useful tool for the diagnosis of NMBA-induced anaphylaxis1,2,20but requires further investigation.Skin tests remain the gold standard for the detection of IgE-mediated reactions by exposing the mast cells of the skin to the suspected allergen in patients having experienced anaphylaxis.8The results of skin testing the third component of the with and/or has not been to prevent tests the tool to (1) identify the culprit agent therefore to (2) prove the pathophysiologic mechanism of the reaction and (3) a safe drug for future exposures (fig. A to after the reaction is required to a test result because of mast cell testing should be according to the clinical to provide a Therefore, all drugs before the reaction, as well as latex, must be skin and immediate hypersensitivity reactions immediate of skin tests (i.e. , after test agents, the cutaneous should be with a and a and/or of drugs is by tests followed by tests using or without the concentrations to results (table are more sensitive but less specific than are more likely to systemic allergic reactions and should be only after if the result is the is by of the corresponding the is concentrations are used with to between the test result is or the concentration is criteria of and the concentrations of anesthetic drugs that are have been defined in (table have been recommended in adapted by and blocking agents are frequently involved during perioperative anaphylaxis at a of according to in are available in the United has not been an of the agents of perioperative anaphylaxis in the United on to the and and because of a of skin overall in the United are unknown. NMBAs may sensitivity of skin tests for NMBAs in patients having experienced anaphylaxis after an NMBA injection is than and is concentration recommended should not be (table between NMBAs is common and to be for cross-reactivity with the other NMBAs should be to identify safe (i.e. , during the diagnostic approach of NMBA-induced and as by cross-reactivity is by followed by because are less sensitive than others recommend an to all NMBAs be as the in of a anaphylaxis to a because this an for the anesthetic for the patient in the particular have suggested an increased of anaphylaxis with in and in leading the Norwegian Agency to an its use for groups may account for this increased was not observed in or in the United Therefore, authors called into the of skin tests in the diagnosis of to NMBAs, that skin test results due to of used by either or might the high incidence were in considered that and of may induce recommended at least before skin testing that results were with for were considered to be either at as in these the is very low of previous clinical predictive of skin tests with NMBAs remain and skin test results are not predictive of of in these the absence of mast cell the skin may be to a direct of NMBAs on cutaneous contrast to skin tests with NMBAs in anaphylactic patients are highly reliable and IgE with corresponding release of inflammatory skin tests in anaphylactic patients and should not be the apparent increased incidence of anaphylaxis to might be due to (1) a of and (2) of of new (3) or (4) requires further in to be of latex is by using sensitivity is available skin test in the United where diagnosis relies on in vitro are often but amount of latex is not by antibiotics involves primarily and which share the may occur at first European Network Allergy on drug hypersensitivity proposed the skin testing concentrations as follows for and most The of skin testing with is between and whereas the sensitivity is tests in patients with suggestive clinical and skin test results with is between and seems to be low and is to the common the of the is also by the to the Therefore, and share a with penicillin and suggested that patients allergic to penicillin or have a incidence of allergic reactions to and but not to with remains with should be a concentration of with should be from a clinical entity from histamine release and observed when the drug is rapidly to or is whereas anaphylaxis to and remains may be skin according to the concentration in to is very histamine the concentration recommended for skin testing should not be (table followed by if are with (table remains uncommon among to local anesthetics is very uncommon and has in because of the use of the of local allergic reactions are due to the common of the local common allergenic cross-reactivity among all local anesthetics to the reactions to local anesthetics remain in local anesthetic such as or including or (also to may also allergic or cross-reactivity among is whereas it is seen in the and is absent between and anesthetics or may be skin according to the concentration in with is rare but is more with than with tests may be with followed by in of risk of anaphylaxis with is approximately in was previously used to blood and the for blood during but it was recently from the products still followed by (up to in of are incidence of anaphylaxis to isosulfan or patent blue is less than blue is very may be skin by followed by (up to for blue because it is a and up to for and contrast agents may also induce anaphylaxis. testing may be to prove the to an diagnosis and to provide subsequent for future anesthetic the of the allergologic assessment should be linked to the clinical A suggestive clinical severe associated with an increased tryptase concentration of tryptase increase does not preclude the to skin tests to the suspected agent the diagnosis of anaphylaxis to this which should be a suggestive clinical not a severe associated with an increase of histamine without a tryptase increase with skin test a nonallergic reaction release with drugs such as and a suggestive clinical severe disturbances of cardiovascular associated with a tryptase increase and a increased baseline tryptase with skin test patients should be given a with to provide to before future anesthetic all patients experiencing an of perioperative anaphylaxis have an allergologic assessment before further The is very In many the allergologic assessment is not of patients is therefore required before any requiring anesthetics which must be in a to a suspected drug or have previous severe immediate reactions during anesthesia are at increased risk of a during subsequent anesthesia is a latex-free environment should be used to prevent a perioperative clinical reaction in patients having experienced clinical manifestations of when to latex, in patients many surgical or procedures of the high incidence of sensitization to and in patients with clinical manifestations of to (e.g. , because of the high of cross-reactivity with latex (also called syndrome contrast, patients are for or are allergic to a drug for antibiotics which may be as perioperative that is not likely to be used during the perioperative period are not considered to be at risk for perioperative should be (1) the suspected culprit (2) anesthetic drugs when the anaphylactic event occurs during (3) the with (4) provide early administration of in of grade III or IV for especially for grade III and IV the patient in the and the surgical if possible when it occurs during of intravenous and an expansion of volume are the key of perioperative management of is no during anaphylaxis for the use of when the clinical its early administration should be the during anaphylaxis, including are associated with either or absent administration of or or the for should be during grade I reactions, whereas of may be necessary during grade II (table Conversely, intravenous administrations of are required in grade III reactions, 1 or 2 min if necessary according to the hemodynamic response and followed by a to prevent the for IV reactions and high of commonly used is to and followed by a in vascular during anaphylaxis might within min, a of the into the with either or is therefore essential to for large and should be is treated with or cases of bronchospasm, intravenous injection of a is and a should be contrast, when cardiovascular collapse and occur remains the to first the cardiovascular homeostasis whereas its is in early in the of are recommended because of are at least and/or are often recommended in the management of have been in of anaphylaxis, and not prevent biphasic anaphylaxis, that patients should be followed up after apparent of anaphylaxis. are useful for to the disturbances of cardiovascular This clinical entity is called anaphylactic to , although it remains in the or for patients is recommended in this clinical of receptors might be one of the contributing factors of occurring during anaphylaxis, may be an through its vasoconstrictive mediated by vascular Another contributing to may involve nitric oxide seems to a during because increased nitric oxide to the hypotension and to during directly intracellular concentrations of the nitric oxide second for the possible use of during may be when in the early of anaphylaxis when are that might be considered as a during anaphylaxis. Therefore, patients experiencing anaphylaxis to and/or were treated with at least min after therefore a in cases of occurring during anaphylaxis. it is important that both and of during during anaphylaxis be such that a assessment of its can be blue is known to with nitric vascular smooth muscle and was recently used in and are to the mechanism and clinical of these anaphylaxis is a severe and rapid clinical condition that can be even in previously The diagnosis of perioperative anaphylaxis might be because the clinical of this can be of very rapid onset with clinical signs. management of perioperative anaphylaxis should therefore be encouraged through such as an anesthesia to for the low with which the anaphylaxis in clinical the of clinical, and skin test evidence identify the culprit agent and the to these agents in future clinical Moreover, the of to cardiovascular homeostasis during anaphylaxis should more especially the of the of in this clinical
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W1975094261
FWCI: 2.511
Cites: 31
Cited by: 306
Related to: 10